Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot randomized trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202004761408382

Enrollment

Registered

2020-04-15

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

IHP Detox tea

Conventional therapy only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with confirmed clinical and laboratory diagnosis of COVID-19. Patients with normal liver and renal function markers.

Exclusion criteria

Exclusion criteria: Pregnant, lactating and breastfeeding women. Patients with diabetes or with serious ailments of heart, liver, kidney or brain. Chronic medical disorders including HIV/AIDS, Cancers, etc. Subjects who have any allergy or were allergic to any of the medication to be used.

Design outcomes

Primary

Measure	Time frame
The mean time to negative test to COVID-19.;Presence of immune determinants.	—

Secondary

Measure	Time frame
Proportion of patients with persisting respiratory symptoms (cough, expectoration, nasal discharge, headache, fever, sore throat, earache, malaise/fatigue and sleep disturbance) ;Incidence of any adverse events (such as diarrhea, nausea, vomiting and colitis) ;Mean levels of renal function parameters (serum electrolyte, urea and creatinine). ;Mean levels of liver function parameters (AST, ALT and ALP) and lipid profiles.;Proportion of patients discharged from hospital or deaths;Effects (if any) on CD4+ and CD8+ counts of both Study Arms	—

Measure

Time frame

Proportion of patients with persisting respiratory symptoms (cough, expectoration, nasal discharge, headache, fever, sore throat, earache, malaise/fatigue and sleep disturbance) ;Incidence of any adverse events (such as diarrhea, nausea, vomiting and colitis) ;Mean levels of renal function parameters (serum electrolyte, urea and creatinine). ;Mean levels of liver function parameters (AST, ALT and ALP) and lipid profiles.;Proportion of patients discharged from hospital or deaths;Effects (if any) on CD4+ and CD8+ counts of both Study Arms

—

Countries

Nigeria

Contacts

Public ContactJude Duru

Consultant

jduruonweni2203@hotmail.com+2348037212638

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026